Investigation of the effect of ginger on ulcerative colitis treatment

Investigation of the effects of Zingiber officinale on quality of life, disease activity index, and Serum levels of some inflammatory factors and oxidative stress in patients with ulcerative colitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201703164010N17

Enrollment

Registered

2017-10-17

Start date

2017-04-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis. Ulcerative colitis, unspecified

Interventions

Intervention 1: the supplement of powdered ginger during12 weeks.4( 0.5gr) capsules daily. Intervention 2: the capsules of placebo (starch) during12 weeks. number4( 0.5 gr) capsules daily.

Treatment - Other

Placebo

the supplement of powdered ginger during12 weeks.4( 0.5gr) capsules daily

the capsules of placebo (starch) during12 weeks. number4( 0.5 gr) capsules daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: cases with ulcerative colitis; Disease duration less than two years; active mild to moderate disease severity; no use of alcohol; Insensitivity to ginger; no disease else; no use of any dietary supplements; Anticoagulant drugs and Non-steroidal anti-inflammatory drugs (NSAIDs) during the last month; BMI over than 18.5 and less than 30; age equal and more than 18 years; tendency to participate in this research; no change in type and dose of drug usage during last month; not pregnancy, not lactation and no use of oral contraceptive drugs in women exclusion criteria: Relapse of disease leading to patient hospitalization; Ginger sensitivity; the patient Unwillingness to continue participation in this research

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum MDA. Timepoint: at the first of research. 6thweek. end of research( 12th week). Method of measurement: Elisa.;Serum hs-CRP. Timepoint: at the first of research. 6thweek. end of research( 12th week). Method of measurement: Elisa.;TNF-a. Timepoint: at the first of research. 6thweek. end of research( 12th week). Method of measurement: Elisa.;TAC. Timepoint: at the first of research. 6thweek. end of research( 12th week). Method of measurement: Elisa.;Life Quality. Timepoint: at the first of research. 6thweek. end of research( 12th week). Method of measurement: Questionnaire.;Disease Activity Index. Timepoint: at the first of research. 6th week. end of research( 12th week). Method of measurement: Questionnaire.	—

Measure

Time frame

Serum MDA. Timepoint: at the first of research. 6thweek. end of research( 12th week). Method of measurement: Elisa.;Serum hs-CRP. Timepoint: at the first of research. 6thweek. end of research( 12th week). Method of measurement: Elisa.;TNF-a. Timepoint: at the first of research. 6thweek. end of research( 12th week). Method of measurement: Elisa.;TAC. Timepoint: at the first of research. 6thweek. end of research( 12th week). Method of measurement: Elisa.;Life Quality. Timepoint: at the first of research. 6thweek. end of research( 12th week). Method of measurement: Questionnaire.;Disease Activity Index. Timepoint: at the first of research. 6th week. end of research( 12th week). Method of measurement: Questionnaire.

—

Secondary

Measure	Time frame
Weight. Timepoint: at the first of research. 6thweek. end of research( 12th week). Method of measurement: scale.;BMI. Timepoint: at the first of research. 6thweek. end of research( 12th week). Method of measurement: Calculation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzita Hekmatdoost

Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences

A_hekmat2000@yahoo.com+98 21522357483

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026